Harbin Pharmaceutical Group Co., Ltd. (HARBIN PHARMACEUTICAL GROUP CO ) Aktie

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium iron zinc oral solutions, zinc gluconate oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, human erythropoietin injections, iron vitamin B12 oral solutions, ceftriaxone sodium injections, Qufenggutong gel cream, GNC Vitapak nutrition package, lacidipine tablets, GNC fish oil, GNC children's liquid calcium magnesium zinc IV, and penicillin and cephalosporin antibiotic preparations. The company sells its products under the Harbin Pharmaceutical, Sanjing, Gaizhonggai, Hutong, Puxue, Hayao, and Shiyitang brands. It is also involved in culture, science and technology, passenger transport, food, property, security, and pharmaceutical investment services, as well as biology and health technology activities. Harbin Pharmaceutical Group Co., Ltd. was founded in 1991 and is based in Harbin, China.